Fatty Liver News and Research

Latest Fatty Liver News and Research

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards.

24 Jul 2015

Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

Approximately 30,000-40,000 people die from liver disease each year, according to the American Liver Foundation. For people who experience acute liver failure, the only proven treatment has been liver transplantation. Researchers at Mayo Clinic have developed and are testing an alternative to liver transplantation called the Spheroid Reservoir Bioartificial Liver that can support healing and regeneration of the injured liver, and improve outcomes and reduce mortality rates for patients with acute liver failure — without requiring a transplant.

20 Jul 2015

UT Southwestern researchers find potential therapy to treat diabetes, nonalcoholic fatty liver disease

Reducing high concentrations of a fatty molecule that is commonly found in people with diabetes and nonalcoholic fatty liver disease rapidly improves insulin sensitivity, UT Southwestern Medical Center diabetes researchers have found.

17 Jul 2015

Genetic mutation associated with severe loss of body fat, appearance of premature aging in children identified

Researchers at the Translational Genomics Research Institute have identified a genetic mutation associated with the appearance of premature aging and severe loss of body fat in children.

17 Jul 2015

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Nutrition Science Initiative has launched the first-ever randomized, controlled clinical trial to determine whether removing added sugars from the diet can halt or even reverse nonalcoholic fatty liver disease (NAFLD) in children.

16 Jul 2015

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has entered into a Research, Option and License Agreement ("License Agreement") and a Share Purchase Agreement with One Way Liver Genomics S.L., for the development of a non-invasive, blood-based companion diagnostic tool.

8 Jul 2015

Fructose stimulates reward system in the brain to a lesser degree than glucose

Fructose not only results in a lower level of satiety, it also stimulates the reward system in the brain to a lesser degree than glucose. This may cause excessive consumption accompanied by effects that are a risk to health, report researchers from the University of Basel in a study published in the scientific journal PLOS ONE. Various diseases have been attributed to industrial fructose in sugary drinks and ready meals.

26 Jun 2015

High fructose consumption can lead to uncontrolled growth of cardiomyocytes, heart attack

'Walk through any supermarket and take a look at the labels on food products, and you'll see that many of them contain fructose, often in the form of sucrose (table sugar)' -- that's how Wilhelm Krek, professor for cell biology at ETH Zurich's Institute for Molecular Health Sciences, summarises the problem with today's nutrition.

18 Jun 2015

Daily sugar-sweetened beverage habit may increase NAFLD risk

A daily sugar-sweetened beverage habit may increase the risk for non-alcoholic fatty liver disease (NAFLD), researchers from the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HRNCA) at Tufts University report today in the Journal of Hepatology.

8 Jun 2015

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

Scientists from the Florida campus of The Scripps Research Institute have been awarded nearly $2.2 million by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health to advance an innovative approach to the treatment of obesity, a serious health problem that affects more than one-third of all Americans.

28 May 2015

Galmed reports net loss of $2.5 million for first quarter 2015

13 May 2015

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).

6 May 2015

Study shows NASH linked to 50% higher death rates compared with NAFLD

Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).

25 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Data revealed today at The International Liver Congress 2015 show that non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).

23 Apr 2015

Study supports use of vitamin E as effective treatment for NASH

Results revealed today at The International Liver Congress 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis.

23 Apr 2015

Study: Alginate-enriched bread can reduce fat digestion, circulatory lipids in NAFLD patients

A study revealed today at The International Liver Congress 2015 has demonstrated that alginate-enriched bread has the potential to inhibit fat digestion and circulatory lipids in patients with non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

May issues of AGA's journals highlight important research updates on liver disease

The May issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important research updates on the most deadly forms of liver disease.

23 Apr 2015

Exercise benefits obese, overweight people with NAFLD

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the western world. A new study published in the Journal of Hepatology shows that exercise, regardless of frequency or intensity, benefits obese and overweight adults with NAFLD.

8 Apr 2015

Fatty Liver News and Research

Latest Fatty Liver News and Research

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

Mayo Clinic researchers test Spheroid Reservoir Bioartificial Liver to treat patients with acute liver failure

UT Southwestern researchers find potential therapy to treat diabetes, nonalcoholic fatty liver disease

Genetic mutation associated with severe loss of body fat, appearance of premature aging in children identified

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Fructose stimulates reward system in the brain to a lesser degree than glucose

High fructose consumption can lead to uncontrolled growth of cardiomyocytes, heart attack

Daily sugar-sweetened beverage habit may increase NAFLD risk

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

Galmed reports net loss of $2.5 million for first quarter 2015

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Study shows NASH linked to 50% higher death rates compared with NAFLD

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Study supports use of vitamin E as effective treatment for NASH

Study: Alginate-enriched bread can reduce fat digestion, circulatory lipids in NAFLD patients

May issues of AGA's journals highlight important research updates on liver disease

Exercise benefits obese, overweight people with NAFLD

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Fatty Liver News and Research

Latest Fatty Liver News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in